NasdaqGS:GHHealthcare
Guardant Reveal Study Spurs Fresh Look At Guardant Health Valuation Risks
Guardant Health (NasdaqGS:GH) reported results from a landmark study of its Guardant Reveal liquid biopsy test for minimal residual disease in resected stage III colon cancer.
The study, conducted with Mayo Clinic and the Alliance for Clinical Trials in Oncology, is described as the largest published analysis of circulating tumor DNA in this setting.
Published in the Journal of Clinical Oncology, the data indicate that Guardant Reveal more accurately predicts recurrence and survival than...